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Abstract 
Objective: Factors associated with poor health in HIV-exposed-uninfected (HEU) infants are 
poorly defined. We describe the prevalence and correlates of CMV viraemia in HEU and 
HIV-unexposed-uninfected (HUU) infants, and quantify associations with anthropometric, 
haematological and immunological outcomes. 
Design: Cross-sectional, including HEU and HUU infants from rural coastal Kenya. 
Methods: Infants aged 2-8 months were studied. The primary outcome was CMV viraemia 
and viral load, determined by quantitative PCR. Correlates were tested by logistic and linear 
regression; coefficients were used to describe associations between CMV viraemia and 
clinical/immunological parameters. 
Results: 42/65 (64.6%) infants had CMV viraemia (median viral load, 3.0 [IQR: 2.7-3.5] 
log10 IU/mL). Compared to community controls, HEU infants had 6-fold increased odds of 
being viraemic (adjusted OR 5.95 [95% CI: 1.82-19.36], P=0.003). Age, but not HEU/HUU 
status, was a strong correlate of CMV viral load (coeff=-0.15, P=0.009). CMV viral load 
associated negatively with weight-for-age z-score (coeff.=-1.06, P=0.008) and head 
circumference-for-age z-score (coeff.=-1.47, P=0.012) and positively with CD8 T cell co-
expression of CD38/HLADR (coeff.=15.05, P=0.003). 
Conclusions: The odds of having CMV viraemia was six-fold greater in HEU than HUU 
infants when adjusted for age. CMV viral load was associated with adverse growth and 
heightened CD8 T cell immune activation. Longitudinal assessments of the clinical effects of 
primary CMV infection and associated immunomodulation in early life in HEU and HUU 
populations are warranted. 
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 Introduction  
Successful prevention of mother-to-child transmission (pMTCT) of HIV-1 strategies 
have given rise to an increased number of HIV-exposed uninfected (HEU) infants over 
the past decade [1]. Despite these gains, higher morbidity and mortality is observed in 
HEU infants compared to infants born to HIV-uninfected mothers (referred to as HIV 
unexposed uninfected [HUU]) [2–5]. Defining the mechanisms of poor health in this 
population is an increasing public health priority.  
  
Numerous factors may disproportionately impact health outcomes in HEU infants, 
including heightened susceptibility to infections [6–8] (which are associated with 
maternal immunopathology [6]), exposure to antiretroviral therapy (ART) and exposure 
to a maternal immune system perturbed by HIV-1 infection (reviewed in [9]). A 
relatively unexplored influence is exposure to maternal co-infections. Cytomegalovirus 
(CMV) is a common maternal coinfection with high sero-prevalence, especially in 
countries that also have high HIV-1 prevalence (80-100% in pregnant women) [10,11]. 
 
Most vertical CMV transmission occurs postnatally, through contact with breast milk, 
maternal saliva, urine or other bodily fluids. Immunocompetent full-term infants who 
acquire CMV postnatally benefit from passive maternal antibodies and generate 
protective immunity leading to what is usually a largely asymptomatic life-long latent 
infection. However, in utero CMV transmission is a leading cause of congenital disease 
and can lead to birth defects, neurodevelopmental deficiencies and hearing loss [12]. In 
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
addition, primary postnatal infection in immunocompromised hosts, including pre-term 
infants, can lead to a range of clinical manifestations [13]. Infant HIV-1/CMV co-
infection has been reported to be particularly severe, with higher viral loads of both 
infections, accelerated disease progression and increased mortality compared to CMV-
uninfected HIV-1 positive infants [14–16]. The effects of primary postnatal CMV 
infection in HEU infants, a population with immunological alterations, remain poorly 
understood.  
 
HEU infants exhibit reduced transfer of specific maternal IgG antibodies in utero [17,18] 
which may lead to reduced protection from CMV infection and delayed control of 
viremia. In addition, phenotypic alterations occur in T cells from HEU infants, including 
expansions of activated and differentiated cells and reductions in circulating naïve cells, 
particularly amongst CD8+ cells [19,20]. Strikingly, CMV infection has broad effects on 
the T-cell compartment in heathy Gambian infants [21] and Malawian children [22], with 
increased expression of differentiation, activation and senescence markers that are 
associated with functional impairments and reduced vaccine responses in elderly adults 
[23]. We previously observed that ex vivo CD8 T cell activation levels varied widely in 
HEU and HUU Kenyan infants [24]. We therefore hypothesised that CMV infection 
disproportionately affects HEU infants in early life, leading to immunomodulation 
including enhanced T cell activation. Consequently, we assessed the prevalence and 
correlates of peripheral blood CMV viremia, a marker principally of primary CMV 
infection, in Kenyan HEU and HUU infants from a rural coastal region. In addition, we 
assess associations between CMV viraemia and anthropometric, haematological and 
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immunological outcomes including ex vivo T cell activation, regulatory T cell (Treg) 
frequencies and frequencies of mature plasmacytoid dendritic cell (pDC). 
 
Methods 
Study design 
A cross-sectional retrospective study design was used. Enrolment specimens were 
obtained from two groups recruited contemporaneously (from 2011-2013) to study 
immune health in HEU infants [25]. Specimens from the first group were from an 
observational cohort of HIV-exposed infants attending the Kilifi County Hospital for 
PMTCT care, a tertiary-level health facility in rural coastal Kenya [26]. PMTCT 
provision was according to Kenyan national guidelines [27] as previously described[26]. 
Infants were recruited through a consecutive sampling approach whereby enrolment 
occurred between 3 and 18 months-of-age, and follow-up occurred at 3-monthly intervals 
until 24 months-of-age [25]. The present study was restricted to specimens from HEU 
infants who were 2-8 months-of-age, who remained HIV-1 negative throughout follow-
up and who had a cryopreserved plasma sample (Supplementary Fig. 1, 
http://links.lww.com/QAD/B117). The second group were 2-8-month-old HUU infants 
recruited from a secondary-level health facility or during an annual malaria 
epidemiological survey, both within the Kilifi County Hospital catchment area, that were 
born to HIV-uninfected mothers and who provided a one-off sample. All infants who met 
these criteria were included (Supplementary Fig. 1, http://links.lww.com/QAD/B117). 
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HIV-1 infection status among all HIV-exposed infants was determined as per Kenyan 
national PMTCT guidelines [27]: by a dried blood spot PCR at 6 weeks of age, by rapid 
antibody test at 9 months and by a confirmatory rapid antibody test at 18 months-of-age. 
Due to ethical considerations HUU infants were not directly screened for HIV-1 
infection. N=22 infants were born to HIV-negative mothers (tested antenatally). 
Antenatal screening data was not available for the remaining N=7 infants (all between 6-
8 months-of-age) classed as HUU. Local HIV-1 prevalence in women aged 25–35 years 
is 4.1% [28]. The severity of HIV-1 pathology in early infancy and low maternal 
prevalence relative to the national average in women (7.6% [29]) made recruitment of 
HIV-1 positive or HEU infants unlikely. Whole-blood samples were collected by a 
clinician at scheduled visits and stored at room temperature until processing. Complete 
blood counts were determined using a Coulter MDII-18 counter (Beckman-Coulter, 
Fullerton, CA). 
 
Plasma storage and CMV viral load determination 
Sample processing was done within 4 hours of venepuncture, and plasma was stored 
continuously at -80°C until use.  Viral nucleic acids were extracted from 200 µL of 
plasma using the QIAamp® MiniElute® Virus Spin Kit (Qiagen, Limburg, Netherlands). 
CMV viral load was determined using the RealStar® CMV PCR Kit 1.0 (Altona 
Diagnostics, Hamburg, Germany) following the manufacturer’s instructions. Real-time 
quantitative PCR was done using the ABI Prism 7500 SDS instrument (Applied 
Biosystems, Waltham, USA). A single 96-well plate run was used for all HEU and HUU 
samples, a negative control and four standards calibrated against the 1st WHO 
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International Standard for Human CMV Nucleic Acid Amplification (these served to 
generate a standard curve, as quality controls and as a positive control). The assay limit 
of detection is estimated to be 92.1 international units (IU)/mL. Viraemia was defined as 
a measurable viral load, as per manufacturer’s recommendations, and viral loads are 
presented as log10 IU/mL of peripheral blood. 
 
Ex vivo immunophenotyping of leucocytes 
Following centrifugation, plasma was removed from packed cells and replaced with 
supplemented RPMI (10% inactivated new-born calf serum, 0.01% β-mercaptoethanol, 
1% penicillin/streptomycin, 1% L-glutamate and 1% HEPES). Fluorescently-labelled 
antibodies in 100μL were incubated at room temperature. All antibodies were from 
Becton Dickinson ( Franklin Lakes, New Jersey) unless stated: anti-CD3 Pacific Blue 
(PB), anti-CD3 allophycocyanin (APC)-H7, anti-CD4 PB, anti-CD4 peridinin 
chlorophyll (PerCP) (Biolegend, San Diego, CA), anti-CD8 APC-H7, anti-HLA-DR 
fluorescein isothiocyanate (FITC), anti-CD38 phycoerythrin (PE)-Cy7 (Biolegend), anti-
PD-1 APC (eBiosciences, San Diego, CA), anti CD25 PE, FOXP3 FITC (eBiosciences), 
anti-lineage FITC, anti-HLA-DR PerCP, anti-CD11c APC, anti-CD123 efluor 450 
(eBiosciences) and anti-CD86 PE. Red blood cell lysis was done using BD FACS lysing 
solution (BD Bioscience) and cells were washed once in phosphate buffered saline before 
acquisition. To detect Tregs the Human Regulatory T Cell Whole Blood staining kit 
(eBiosciences) was used per the manufacturer’s instructions. Following permeabilisation, 
cells were blocked with 2% rat serum and incubated with anti-FOXP3 (clone PCH101). 
Tregs were defined as CD25hi FOXP3+ CD4 T cells (Supplementary Fig. 2D, 
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http://links.lww.com/QAD/B117). Plasmacytoid DCs (pDCs) were defined as lineage- 
HLADR+ CD123+ leucocytes (Supplementary Fig. 3, http://links.lww.com/QAD/B117) 
[30]. Isotype controls (Becton Dickinson) matched for concentration and processed under 
the same conditions as cells were used to set positive gates for all markers except CD3, 
CD4, CD8 and CD25. 
 
Flow cytometry 
Flow cytometry was done on a Cyan ADP (Beckman Coulter) with 3 lasers and 9 
fluorescence channels, with Summit 4.3 software. Single-stain compensation controls 
were set using anti-mouse kappa beads (BD Bioscience) and the respective 
fluorochrome-conjugated antibody for all experiments.  A minimum of 70,000 CD3+ 
events and 200,000 events in the leucocyte gate were collected for T cell phenotyping 
and pDC phenotyping, respectively. To minimize doublet events, event acquisition rate 
alterations were minimized (Supplementary Fig.2A, http://links.lww.com/QAD/B117). 
 
Data analysis 
Flow cytometry compensation and analysis was done in FlowJo version 7.6 for PC 
(Treestar, Ashland, Oregon). FlowJo templates were made for consistent gating. FlowJo 
tables were exported into STATA v.12 (Stata Corp, College Station, Texas) for analyses.  
 
The 2006 WHO growth standard references [31] were used to generate weight-for-age 
(WAZ), height-for-age (HAZ), weight-for-height (WHZ) and head circumference-for-age 
standard deviation (Z)-scores using the STATA igrowup package. A distribution of the 
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participant characteristics was done. Continuous data were presented using medians 
(interquartile ranges, IQR). 
 
The primary outcome of the study is peripheral blood CMV viraemia, and is presented as 
a prevalence of all infants. Correlates of CMV viremia and CMV viral load were 
determined using multivariable logistic and linear regression, respectively. Crude and 
adjusted odds ratios (OR), their 95% CI and likelihood ratio test (LRT) P values are 
presented. Multivariable linear regression was used to assess the relationships between 
CMV viral load and anthropometric, haematological immunological outcomes. Whole 
blood cell counts were log transformed (log10) before inclusion in regression models. 
Multiple comparison correction was made independently for grouped outcomes using the 
Dunn–Šidák method; due to the limited sample size of the study alpha was set at 0.1. For 
baseline differences, differences in maternal characteristics and in the subset of infants 
with immunological data, Chi squared tests were used for categorical variables and 
unpaired t tests or Mann-Whitney tests were used to compare continuous variables.  
 
Ethical considerations 
The study protocol was reviewed and approved by the Kenyan Medical Research Institute 
Ethical Research Council (KEMRI-ERC; protocol no. SSC 2085) and the Oxford 
Tropical Research Ethics Committee (OxTREC; ref: 45-11). Informed consent was 
obtained from caregivers that accompanied the infants to the health facilities. 
 
Results 
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Study participants 
Overall, 65 infants were studied (Table 1): 36 HEU (median age 4.2 months [IQR 3.3 to 
4.9]) and 29 HUU (median age 3.5 months [IQR 2.8 to 5.6]). No significant baseline 
differences between HEU and HUU infants were observed with regards to age and sex, 
though HEU infants had increased lymphocyte counts (P=0.04). 
 
HIV-exposure is strongly associated with having CMV viraemia  
A total of 42/65 infants were found to be CMV viraemic: 29/36 (81%) among HEU and 
13/29 (45%) among HUU infants (Chi sq. test P=0.004). In multivariate analyses and 
after adjusting for age and sex, HEU infants had a six-fold increased odds of being CMV 
viraemic, compared to HUU infants (adjusted OR 5.95 [95% CI: 1.82 to 19.36], p=0.003; 
Table 2).  
 
CMV viral load is strongly associated with infant age 
Median viral load among all 42 CMV viraemic infants was 3.0 (IQR: 2.6-3.5) log10 
IU/mL: 3.1 [IQR: 2.7-3.5] log10 IU/mL among HEU infants and 2.7 (IQR: 2.4-3.2) log10 
IU/mL among HUU infants (P=0.161). HIV exposure status was not associated with 
CMV viral load (P=0.142) when adjusted for age and sex. Age had a strong negative 
correlation (coeff -0.15 per month of age, P=0.009) with CMV viral load, but there was 
no association with sex (P=0.55) (Table 2 and fig. 1). 
 
Anthropometry parameters correlate with CMV viraemia  
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Having CMV viraemia was not associated with any anthropometry outcome when 
adjusted for age, sex, HIV exposure and multiple comparisons (Supplementary Table 1, 
http://links.lww.com/QAD/B117). However, among CMV viraemic infants, CMV viral load 
had strong effects on WAZ (coeff. -1.06, P=0.008), head circumference-for-age Z score 
(coeff. -1.47. P=0.012) and a trend towards an effect on HAZ (coeff -2.36 P=0.034) 
following adjustments for age, sex, HIV exposure and multiple comparisons (Table 3 
and Fig. 2A, B & D; significance considered at P<0.025). No effect was observed on 
WHZ following adjustments (coeff. 1.10, P=0.094; Table 3 & Fig. 2C). 
 
Associations between whole blood cell counts and CMV viraemia  
A strong positive correlation was seen between having CMV viraemia and lymphocyte 
percentage (coeff. 12.08, P=0.007) and a trend towards a negative correlation was seen 
between having CMV viraemia and neutrophil count (coeff. -0.29, P=0.033) when 
adjusted for age, sex, HIV exposure and for multiple comparisons (Supplementary 
Table 1, http://links.lww.com/QAD/B117; significance considered at P<0.013). No effect 
was observed in relation to the remaining haematological parameters analysed. No 
significant effect of CMV viral load was observed on any haematological parameters 
following adjustments (Table 3).  
 
CMV viraemia is strongly associated with increased immune activation in ex vivo 
CD8 T cells  
HLADR/CD38 co-expression on T cells is a useful activation marker in the context of 
constitutive CD38 expression on infant T cells[32–34]. We found no significant 
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
differences between ex vivo activated CD8 T cells in 2-5-month-old HEU and HUU 
infants (Table 1); however, we observed wide variation (range: 2.5-75.4%) in the 
percentage of activated CD8 T cells, irrespective of HIV-exposure status. We therefore 
assessed the relationship between CMV viraemia and the frequency of ex vivo leucocytes 
including activated (HLADR+ CD38+) and PD-1+ CD4 and CD8 T cells, Tregs and 
mature (CD86+) pDCs. This analysis was restricted to the 2-5-month-old infants for 
whom immunophenotypic data had been previously generated using fresh whole blood 
(Supplementary Fig.1, http://links.lww.com/QAD/B117). These infants did not differ 
significantly in HIV exposure, gender distribution, growth Z-scores or haematology from 
the overall infant population (Supplementary Table 2, http://links.lww.com/QAD/B117).  
 
No significant correlation was seen between having CMV viraemia and T cell activation, 
Treg frequencies and the frequency of CD86+ pDCs when adjusting for age, sex, HIV 
exposure and for multiple comparisons (Supplementary Table 1, 
http://links.lww.com/QAD/B117; significance P<0.017). However, CMV viral load 
correlated strongly with HLADR/CD38 co-expression on CD8 T cells (coeff.=15.05, 
P=0.003) following adjustments age, sex, HIV exposure and for multiple comparisons 
(Table 3 and Fig. 2D). No significant correlations were observed between CMV viral 
load and any other immunological outcomes (Table 3).  
 
Amongst HEU infants, maternal health markers were not associated with detection 
of CMV viraemia  
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To assess effects of maternal health on detection of CMV viraemia, we assessed maternal 
HIV-1 viral load at infant birth, ART duration, CD4 count at infant birth and body mass 
index at infant birth. Maternal data was only available for HEU infants. No significant 
differences were observed in maternal health indicators between groups based on the 
presence of infant CMV viraemia (Supplementary Table 3, 
http://links.lww.com/QAD/B117). 
 
Discussion 
Much attention has been paid to the impact of HIV and ART exposure on adverse 
delivery outcomes [35,36], metabolic [37,38] and haematological [39,40] abnormalities 
and immunological alterations [41,42] in HEU infants. The impact of maternal co-
infections on HEU infant health is relatively under-explored and may directly impact 
some of the outcomes mentioned above. We assessed the burden and possible risk factors 
for systemic CMV replication in infancy in HEU and HUU infants and explored 
associations between CMV viraemia and anthropometric, haematological and 
immunological outcomes. Our main findings were: 1) a 6-fold increased odds ratio of 
CMV viraemia in HEU infants compared to HUU infants; 2) a strong negative 
association between CMV viral load and infant age; 3) significant negative associations 
between CMV viral load and infant weight-for-age and head circumference-for-age Z 
scores; and 4) a significant positive association between CMV viral load and CD8 T cell 
activation. 
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CMV viraemia has been detected in >90% of Kenyan [14] and Gambian infants (HEU 
and unknown HIV exposure, respectively) [43], and in lower proportions in South 
African [44] and Zambian [45] infants. A recent retrospective study of a large number of 
Zimbabwean HEU and HUU infants from the ZVITAMBO cohort [46] found similar 
high CMV prevalence rates at 6 weeks-of-age, though no significant differences between 
well-matched HEU and HUU infants. However, significantly higher median viral loads 
were observed in HEU infants. Our contrasting observations may be best explained by 
differences in background levels of CMV viraemia (74% of HUU infants at 6 weeks-of-
age vs 45% of 2-8-month-old infants in our study), highlighting the importance of region-
specific studies. In addition, the focus on one time point in the ZVITAMBO study may 
have led to underestimations of CMV viraemia in infant groups, limiting the ability to 
detect differences throughout infancy and assess the effect of age in modulating CMV 
viral load. Nevertheless, the study was conducted in an era before ART was available for 
PMTCT and in this setting, differences between HEU and HUU infant groups, such as 
median infant CMV viral load, may have been more pronounced.  
 
We found infant age to be a critical factor associated with CMV viral load control, 
suggesting a role for de novo infant immunity in limiting systemic viral replication. 
However, extended low-level replication has been reported in longitudinal assessments of 
CMV viremia in infancy [14], suggesting functional limitations of de novo CMV-specific 
adaptive response, particularly in CD4 T cells [47]. As CMV viral load is associated with 
clinical sequelae following congenital infection [48] and symptomatic acute infection 
[45], longitudinal studies are needed to evaluate the relationship between age of primary 
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infection, peak CMV viral load and clinical and immunological outcomes of HIV-
exposed and unexposed infants.  
 
We assessed the impact of viral load on anthropometry adjusting for age, sex and HIV 
exposure status. In a previous study comparing HIV-exposed and unexposed Zambian 
infants, CMV infection was associated, at 18 months of age, with reduced HAZ-scores 
irrespective of HIV exposure, and with reduced head circumference-for-age scores and 
psychomotor development in HEU infants [49]. Furthermore, the prevalence of stunting 
at 18 months of age was found to be three times higher in CMV seropositive HIV 
exposed and unexposed children. Similarly, breast milk CMV load has been inversely 
correlated with HAZ and WAZ-scores at 6 months of age in HEU infants [50]. 
Accordingly, our data indicate a significant negative association between CMV viral load 
and WAZ and head circumference-for-age Z scores. Our analysis limits causative 
inferences to be made, however, the consistency of the association of anthropometric 
parameters with CMV viral load across studies (reviewed in [51]) indicates a negative 
influence on infant growth from an early age. Studies assessing CMV viral load and 
neurocognitive outcomes in infancy are warranted.  
 
Numerous studies describe phenotypic changes in ex vivo leucocytes in HEU infants [52–
54]. In particular, increased levels of activated (CD38hi) and antigen-experienced 
(CD45RO+) CD8 T cells have been reported in HEU infants and adolescents [19,20], 
though not consistently [24,55,56]. As CMV infection is associated with broad 
phenotypic changes in CD8 T cells [21,57], including activated and antigen-experienced 
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cells, we speculated that CMV infection impacts early immune phenotypes in HEU and 
HUU infants. We observed a strong correlation between CD8 T cell activation and CMV 
viral load, indicating that CMV infection may influence bulk CD8 T cell phenotypes non-
specifically. Coupled with an increased likelihood of early CMV viraemia in HEU 
infants, these data suggest that CMV infection may be a strong driver of cellular immune 
activation in HEU cohorts. Recent findings have also suggested that generalised 
inflammation, measured through C-reactive protein levels, is modulated by maternal 
HIV-1 viraemia more strongly than by infant CMV viraemia[46]. Future studies are 
needed to better understand the complex relationship between HIV exposure, immune 
activation/inflammation and, potentially, infant growth [58]. Our findings support the 
idea that CMV viraemia may serve an important correlate in these studies, and in future 
studies assessing infant T cell immunity. Our data also support the notion that CMV viral 
load may be important when assessing infant outcomes in the context of infant 
malnutrition, as immune activation and inflammation are increased in malnourished 
infants[59].   
 
Our data has several strengths and limitations. Strengths include the combination of 
anthropometric, detailed immunological and virological data in a cohort of HEU and 
unexposed control infants from the same ethnic group and community. Limitations 
include a cross-sectional evaluation over a narrow age, the consequent lack of 
information about the timing of CMV transmission, assessment of CMV viraemia in a 
single compartment and lack of clinical follow-up including data on prematurity. Based 
on the low prevalence of congenital CMV acquisition in other studies [43,50,60,61], we 
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assume that in this study the majority of infections were primary postnatal infection, most 
likely through breastmilk exposure. In addition, consistent with an acute viral infection, 
we observed a strong positive effect of the presence of CMV viraemia on lymphocyte 
percentage. However, we cannot exclude the possibility of observing systemic viral 
replication due to CMV end organ disease, possibly associated with preterm delivery, as 
the low HAZ scores reported may suggest prematurity or in utero effects. Furthermore, 
we were unable to evaluate breastfeeding practices, a key factor associated with postnatal 
CMV acquisition. However, we did evaluate the influence of markers of maternal health 
on detection of CMV viremia, albeit only in HEU infants. Maternal immunosuppression 
and HIV-1 viremia has been associated with CMV shedding in cervical secretions, saliva 
and breastmilk [62–64]. We found no association between maternal health and detection 
of infant CMV viral load in early life. This may be a result of the low number of infants 
in the analysis and the high infection rates in this setting, which further reduced the 
number of infants in the group with no CMV viremia. 
 
Conclusion 
We find a six-fold increased odds of early CMV viraemia in HEU infants compared to 
their unexposed counterparts. Our data also indicate that increased CMV viraemia is 
associated with impaired growth, as well as with CD8 T cell activation. Our findings, 
together with those of others, suggest that increased early CMV transmission may be an 
important factor in the poor health of HEU infants. Further longitudinal assessments of 
the effects of CMV on growth, development and immunomodulation in early life in HEU 
and HUU populations are warranted.
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 Table 1. Characteristics of HIV-exposed uninfected (HEU) and HIV-unexposed 
uninfected (HUU) infants recruited from a rural coastal region in Kenya 
Characteristic   P value  
Demography and 
CMV infection 
HEU (n=36) HUU (n=29)  Total (n=65) 
Female (%) 17 [47.2] 16 [55.2] 0.53 33 [50.8] 
Age in months, 
median [IQR] 
4.2 [3.3, 4.9] 3.5 [2.8, 4.5] 0.07 3.9 [3.2, 4.9] 
Anthropometry, 
median [IQR]  
HEU (n=31) HUU (n=22)  Total (n=53)* 
Weight for age z-
scores 
-0.7 [-1.0, 0.2] -0.4 [-1.2, 0.5] 0.63 -0.6 [-1.1, 0.4] 
Height for age z-
scores 
-1.5 [-2.7, -0.2] -1.2 [-2.8, 1.6] 0.22 -1.3 [-2.7, 0.4] 
Weight for height 
z-scores 
0.6 [-0.4, 1.3] 0.1 [-1.0, 2.1] 0.53 0.6 [-0.5, 1.7] 
Head 
circumference z-
scores 
0.3 [-0.8, 0.8] 0.4 [-0.5, 1.8] 0.19 0.3 [-0.6, 1.0] 
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Haematology, 
median [IQR]  
HEU (n=30) HUU (n=28)  Total (n=58)* 
Red blood cell 
count (106/μL) 
4.3 [4.0, 4.8] 4.3 [3.8, 4.8] 0.80 4.3 [3.9, 4.8] 
White blood cell 
count (109/L) 
10.4 [7.3, 12.8] 9.2 [7.5, 10.9] 0.28 9.7 [7.3, 11.7] 
Haemoglobin count 
(g/dL) 
10.0 [10.0, 11.0] 9.9 [9.1, 10.8] 0.31 10.0 [9.5, 11.0]
Platelet count 
(109/L) 
426.0 [315.0, 
516.0] 
472.0 [400.0, 
568.0] 
0.22 439.0 [335.0, 
542.0] 
Absolute 
lymphocyte count 
(109/L) 
6.8 [5.0, 9.6] 6.1 [4.9, 7.6] 0.04 6.6 [5.0, 8.0] 
Lymphocyte % 73 [65, 76] 69 [63, 73] 0.16 72 [63, 75] 
Absolute 
neutrophil count 
(109/L) 
1.7 [1.1, 2.4] 1.5 [1.3, 2.0] 0.91 1.6 [1.2, 2.2] 
Neutrophil % 17.0 [13.0, 23.0] 17.8 [15.3, 
23.7] 
0.57 17.7 [14.0, 
23.7] 
Immunology, 
median [IQR]  
HEU (n=17) HUU (n=10)  Total 
(n=27)** 
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% CD38+ 
HLADR+ CD8 T 
cells 
37.8 (23.3, 51.2) 48.6 (14.2, 
63.1) 
0.32 40.2 (22.5, 
54.6) 
% CD38+ 
HLADR+ CD4 T 
cells 
3.2 (2.4, 5.7) 6.4 (4.8, 8.3) 0.03 4.2 (2.9, 7.2) 
% PD1+ CD8 T 
cells 
22.7 (13.3, 27.5) 28.3 (16.2, 
40.9) 
0.16 22.7 (13.8, 
29.4) 
% PD1+ CD4 T 
cells 
8.7 (5.0, 12.9) 12.7 (9.0, 13.2) 0.12 9.7 (5.7, 13.1) 
% CD25hi FOXP3+ 
CD4 T cells 
4.5 (3.2, 5.5) 5.1 (2.8, 6.1) 0.65 4.6 (3.1, 5.9) 
% CD86+ pDC 33.0 (20.3, 37.6) 26 (17.8, 38.4) 0.80 27.2 (19.2, 
37.6) 
*Infants with missing anthropometry (N=12) and haematology (N=7) data 
** 2-5-month-old infants only for whom ex vivo immunophenotypic data had been 
previously generated by fresh whole blood immunophenotyping 
Chi squared tests were used for comparisons of categorical variables. Unpaired t tests or 
Mann-Whitney tests were used to compare continuous variables, depending on the 
distribution of the data. 
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 Table 2: Correlates of being CMV viraemic in all infants (model 1) and of the 
magnitude of CMV viraemia (model 2) amongst viraemic infants  
Independent 
variable  
    
Model 1 (N=65) Crude OR [95% 
CI] 
P 
value 
Adjusted OR [95% 
CI] 
*P 
value
HIV exposed 
uninfected  
5.10 [1.69, 15.37] 0.004 5.95 [1.83, 19.36] 0.003 
Female 0.48 [0.17, 1.36] 0.168 0.37 (0.11, 1.24) 0.108 
Age (months) 1.19 [0.84, 1.67] 0.324 1.06 (0.74, 1.53) 0.740 
Model 2 (N=42) Crude linear 
regression 
coefficient [95% 
CI] 
P 
value 
Adjusted linear 
regression coefficient 
[95% CI] 
**P 
value
HIV exposed 
uninfected  
0.28 (-0.12, 0.69) 0.161 0.27 (-0.10, 0.64) 0.142 
Female 0.48 (0.17, 1.36) 0.168 0.11 (-0.26, 0.47) 0.549 
Age (months) -0.17 (-0.27, -0.06) 0.004 -0.15 (-0.27, -0.04) 0.009 
OR, odds ratio  
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* Adjusted P-values for multivariable logistic regression model including age, sex and 
HIV exposure 
**Adjusted P-values from multivariable linear regression model including age, sex and 
HIV exposure 
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 Table 3. Correlations between CMV vireamia and anthropometry, haematology and 
immunological parameters amongst CMV viraemic infants 
Characteristics *Adjusted linear 
regression coefficient 
[95% CI] 
P value 
Anthropometry (N=33)* 
Weight for age z-scores -1.06 (-1.82, -0.29)  0.008 
Height for age z-scores -2.36 (-4.52, -0.188) 0.034 
Weight for height z-scores 1.10 (-0.20, 2.41) 0.094 
Head circumference z-scores -1.47 (-2.59, -0.35) 0.012 
Haematology (N=42)** 
Red blood cell count (106/μL) 0.02 (-0.05, 1.01) 0.474 
White blood cell count (109/L) 0.22 (-0.01, 0.45) 0.058 
Haemoglobin count (g/dL) 0.04 (-0.04, 0.11) 0.342 
Platelet count (109/L) 0.26 (-0.25, 0.77) 0.305 
Absolute lymphocyte count (109/L) 0.21 (-0.07, 0.50) 0.136 
Lymphocyte % 0.89 (-7.38, 9.16) 0.826 
Absolute neutrophil count (109/L) 0.05 (-0.32, 0.42) 0.790 
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Neutrophil % -2.01 (-9.89, 5.87) 0.605 
Immunology (N=19)   
% CD38+ HLADR+ CD8 T cells 15.05 (6.10, 23.99) 0.003 
% CD38+ HLADR+ CD4 T cells 2.37 (0.34, 4.40) 0.026 
% PD1+ CD8 T cells 6.33 (-3.49, 16.16) 0.189 
% PD1+ CD4 T cells 1.07 (-3.33, 5.51) 0.606 
% CD25hi FOXP3+ CD4 T cells -0.47 (-1.92, 0.98) 0.500 
% CD86+ pDC 8.35 (-1.87, 18.58) 0.102 
*Values are adjusted for HIV exposure, age and sex  
**Infants with missing anthropometry (n=12) and hematology (n=7) data
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 Figure 1. Age is strong correlate for CMV viraemia. Scatter plot with a linear 
regression line indicating the relationship between infant age and CMV viral load 
amongst 42 CMV viraemic infants. The correlation coefficient is shown in a 
multivariable regression model following adjustments for HIV exposure and gender. 
Open triangles represent HIV-unexposed uninfected (HUU) infants and filled squares 
HIV-exposed uninfected infants (HEU). 
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 Figure 2: Relationship between CMV viraemia and anthropometry outcomes and T 
cell phenotypes. (A-D) Scatter plots with a linear regression line indicating the 
relationship between CMV viral load and infant weight-for-age, height-for-age, weight 
for height and head circumference for age Z scores (N=33). Following the Dunn–Šidák 
correction for multiple comparisons, significance was considered at p< 0.015. (E-I) 
Scatter plots with a linear regression line showing for the relationship between CMV 
viral load and T cell phenotypes (N=19). Following the Dunn–Šidák correction for 
multiple comparisons, significance was considered at p< 0.026. For all plots, the 
correlation coefficient is shown in a multivariable regression model following 
adjustments for age, gender and HIV exposure. For all plots, HUU infants are indicated 
as open triangles and HEU infants as filled squares.  
A)             B)         C) 
 
D)             E)         F) 
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